NEK9, a novel effector of IL-6/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation
Guofang Lu, Siyuan Tian, Yi Sun, Jiaqiang Dong, Na Wang, Jiaoxia Zeng, Yongzhan Nie, Kaichun Wu, Ying Han, Bin Feng, Yulong Shang
Abstract
This study demonstrates that activation of STAT3 by IL-6 transcriptionally suppresses miR-520f-3p and diminishes the inhibitory effects of miR-520f-3p on NEK9 and GP130. An increase in GP130 enhances this signaling, and NEK9 directly influences cell motility and RhoA activation by targeting the phosphorylation of ARHGEF2. Targeting the IL-6-STAT3-NEK9 pathway may be a new strategy for GC treatment.
Topics & Concepts
MetastasisCancer researchPhosphorylationSTAT3EffectorCancerCancer cellMedicineChemistryBiologyInternal medicineCell biologyImmunologyCytokine Signaling Pathways and InteractionsProtein Tyrosine PhosphatasesCancer, Hypoxia, and Metabolism